Investigation of the Cellular Effects of Beta- Cyclodextrin Derivatives on Caco-2 Intestinal Epithelial Cells.
NF-κB
autophagy
cyclodextrins
endocystosis
lysosomes
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
25 Jan 2021
25 Jan 2021
Historique:
received:
17
12
2020
revised:
18
01
2021
accepted:
20
01
2021
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
Cyclodextrins are widely used excipients for increasing water-solubility, delivery and bioavailability of lipophilic drugs. By using fluorescent cyclodextrin derivatives, we showed previously that cyclodextrins are able to enter Caco-2 intestinal cells by endocytosis, but the influence of different fluorescent labeling on the same cyclodextrin derivative has not been studied. The consequences of the cellular internalization of cyclodextrins have not been revealed yet either. The aims of this study were to compare the cellular internalization of fluorescein- and rhodamine-labeled (2-hydroxypropyl)-, (HPBCD) and randommethyl-β-cyclodextrins (RAMEB) and to investigate the intracellular effects of these derivatives on Caco-2 cells. Stimulation of the NF-kappa B pathway and autophagy and localization of these derivatives in lysosomes were tested. The endocytosis of these derivatives was examined by fluorescence microscopy and flow cytometry. Both fluorescein- and rhodamine-labeled derivatives entered the cells, therefore the type of the fluorescent labeling did not influence their internalization. Cyclodextrin pretreatment did not activate the translocation of the p65 subunit of the NF-kappa B heterodimer into the cell nuclei from the cytoplasm. After HPBCD or RAMEB treatment, formation of the autophagosomes did not increase compared to the control sample and at the same time these derivatives could be detected in lysosomes after internalization.
Identifiants
pubmed: 33504045
pii: pharmaceutics13020157
doi: 10.3390/pharmaceutics13020157
pmc: PMC7911713
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
ID : FK124634
Organisme : Magyarország Kormánya
ID : EFOP-3.6.1-16-2016-00022
Organisme : Magyarország Kormánya
ID : GINOP-2.3.3-15-2016-00021
Références
Commun Integr Biol. 2018 Mar 13;11(2):1-4
pubmed: 30083284
Eur J Pharm Sci. 2010 Jul 11;40(4):376-80
pubmed: 20434542
PLoS One. 2017 Jan 19;12(1):e0170537
pubmed: 28103316
Nutrients. 2018 Jul 03;10(7):
pubmed: 29970869
Int J Pharm. 2015 Dec 30;496(2):509-17
pubmed: 26498369
Methods Mol Biol. 2008;440:15-33
pubmed: 18369934
Toxicol Lett. 2012 Jun 20;211(3):289-95
pubmed: 22561171
J Acquir Immune Defic Syndr (1988). 1993 Mar;6(3):227-30
pubmed: 8450395
J Cell Sci. 2006 Nov 15;119(Pt 22):4758-69
pubmed: 17077125
J Pathol. 2010 May;221(1):3-12
pubmed: 20225336
Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5477-82
pubmed: 20212119
J Biol Chem. 1995 Jul 21;270(29):17250-6
pubmed: 7615524
EMBO J. 2011 Aug 31;30(17):3481-500
pubmed: 21878991
Pediatr Neurol. 2018 Mar;80:24-34
pubmed: 29429782
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Int J Nanomedicine. 2017 Apr 28;12:3433-3446
pubmed: 28496320
Toxicol In Vitro. 2010 Aug;24(5):1441-9
pubmed: 20406675
Biomolecules. 2019 Nov 28;9(12):
pubmed: 31795222
Int J Pharm. 2019 Jun 10;564:59-76
pubmed: 30959238
J Cell Biol. 1993 Dec;123(5):1107-17
pubmed: 8245121
Genes Dev. 2007 Nov 15;21(22):2861-73
pubmed: 18006683
Lancet. 2017 Oct 14;390(10104):1758-1768
pubmed: 28803710
PLoS One. 2014 Jan 08;9(1):e84856
pubmed: 24416301
FEBS Lett. 2005 Mar 14;579(7):1707-14
pubmed: 15757665
Chem Phys Lipids. 2012 Jul;165(5):505-11
pubmed: 22503802
Immunology. 2005 Dec;116(4):513-24
pubmed: 16313365